ecrin-mdr-crcClinical2022IPD Sharing (as of March 2023): NoColorectal CarcinomaColorectal NeoplasmsColorectal CarcinomaColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/13857China9OxaliplatinCapecitabineBevacizumabECRIN MDRRecruitingfalseQL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCThis is an open-label, muticenter phase II study to evaluate the efficacy and safety of QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment of unresectable advanced or metastatic CRC.2022-09-1513857NCT05799820